Welcome to CSNpharm! For Research Use Only!
Home
+1-708-781-1677
sales@csnpharm.com
HIF
| Cat. No. | Product Name | CAS No. | Information |
|---|---|---|---|
| CSN18362 | THS-044 | 62054-67-5 | THS-044 binding stabilizes the HIF2 PAS-B folded state for regulating HIF2 activity in endogenous and clinical settings |
| CSN19042 | SYP-5 | 1384268-04-5 | SYP-5 is a HIF-1 inhibitor suppresses tumor cells invasion and angiogenesis |
| CSN18393 | PX-478 Dihydrobromide | 685898-44-6 | PX-478 target on HIF-1α, which can selectively inhibit the hypoxia-induced increase in HIF-1a protein. |
| CSN17993 | PT-2385 | 1672665-49-4 | PT2385 is an inhibitor of hypoxia inducible factor HIF-2 alpha with antineoplastic effect |
| CSN17994 | PT-2385 R-Enantiomer | 1672666-67-9 | PT-2385 R-enantiomer is the R-enantiomer of PT-2385 which is a potent HIF-2 inhibitor and is a potential anticancer agent |
| CSN20370 | PHD-1 Inhibitor C54 | 2009344-53-8 | PHD-1 inhibitor C54 is a 4-1,2,4triazolo1,5-apyridin-5-ylbenzonitrile-based inhibitor of the hypoxia-inducible factor (HIF) prolylhydroxylase domain-1 (PHD-1). It exhibits reasonable peripheral exposure but poor brain levels (Kp,uu 0.02 and BP 0.03). |
| CSN20369 | PHD-1 Inhibitor C53 | 2009345-20-2 | PHD-1 inhibitor C53 is a 4-1,2,4triazolo1,5-apyridin-5-ylbenzonitrile-based inhibitor of the hypoxia-inducible factor (HIF) prolylhydroxylase domain-1 (PHD-1). It exhibits excellent peripheral exposure, but does not partition well into the brain (Kp,uu 0.39 and BP 0.21). |
| CSN20368 | PHD-1 Inhibitor C39 | 2009343-19-3 | PHD-1 inhibitor C39 is a 4-1,2,4triazolo1,5-apyridin-5-ylbenzonitrile-based inhibitor of the hypoxia-inducible factor (HIF) prolylhydroxylase domain-1 (PHD-1) with high solubility and permeability. |
| CSN20367 | PHD-1 Inhibitor C17 | 2009343-14-8 | PHD-1 inhibitor C17 is an early lead compound of 4-1,2,4triazolo1,5-apyridin-5-ylbenzonitrile-based inhibitors of the hypoxia-inducible factor (HIF) prolylhydroxylase domain-1 (PHD-1) showing a moderate rate of microsomal turnover in vitro. |
| CSN11607 | Oltipraz | 64224-21-1 | Oltipraz can inhibit the insulin-activated HIF-1 (IC50 10 M) in a time-dependent manner. |
| CSN14671 | Moracin O | 123702-97-6 | Moracin O and moracin P exhibit potent in vitro inhibitory activity against hypoxia-inducible factor HIF-1 which is a key mediator during adaptation of cancer cells to tumour hypoxia |
| CSN16636 | ML228 | 1357171-62-0 | ML228 is an activator of the Hypoxia Inducible Factor HIF pathway and potently activate HIF in vitro as well as its downstream target VEGF |
| CSN19680 | MK-8617 | 1187990-87-9 | MK-8617 is a potent, selective, orally bioavailabl pan-inhibitor of hypoxia-inducible factor prolyl hydroxylase 1−3 (HIF PHD1−3), inhibiting PHD1, 2, 3 with IC50s of 1.0, 1.0 and 14 nM, respectively. |
| CSN20474 | LW6 | 934593-90-5 | LW6 is an inhibitor of HIF-1 with IC50 of 4.4 μM. |
| CSN17251 | KC7F2 | 927822-86-4 | KC7F2 is a selective HIF-1 transcription inhibitor with IC50 of 20 M in a cell-based assay |
| CSN17541 | JNJ-42041935 | 1193383-09-3 | JNJ-42041935 is a selective inhibitor of prolyl hydroxylase (PHD) with the pKis of 7.91 0.04, 7.29 0.05, and 7.65 0.09 for PHD1, PHD2, and PHD3, respectively. |
| CSN16064 | IOX2 | 931398-72-0 | IOX2 is a selective inhibitor of the hypoxia inducible factor HIF Prolyl-Hydroxylases PHD and active in cells with IC50 value of 21 nM for PHD2ELGN-1 and no inhibition at FIH20uM |
| CSN20256 | IDF-11774 | 1429054-28-3 | IDF-11774 is a hypoxia-inducible factor HIF-1 inhibitor which regulates cancer metabolism thereby suppressing tumor growth |
| CSN18038 | HIF-2α-IN-1 | 1799948-06-3 | HIF-2-IN-1 is a HIF-2 inhibitor has an IC50 of less than 500 nM in HIF-2 scintillation proximity assay |
| CSN20613 | GSK360A | 931399-19-8 | GSK360A is an active HIF-PHD inhibitor with systemic and local effects by stabilizing HIF-1 signaling and can improve long-term ventricular function |
| CSN16866 | FG-2216 | 223387-75-5 | FG-2216 is a potent HIF-prolyl hydroxylase inhibitor with IC50 of 39 M for PHD2 enzyme orally bioavailable and induced significant and reversible Epo induction in vivo |
| CSN22394 | Enarodustat | 1262132-81-9 | Enarodustat is a potent and orally active factor prolyl hydroxylase inhibitor with an EC50 of 022 M Enarodustat has entered clinical trial for renal anemia |
| CSN17599 | EL-102 | 1233948-61-2 | EL102 is an inhibitor of HIF1 Which can inhibit tubulin polymerisation and decreased microtubule stability |
| CSN20491 | Echinomycin | 512-64-1 | Echinomycin is a highly potent and selective HIF-1 inhibitor IC50 294 pM which selectively inhibits HIF-1 binding to the VEGF promoter without affecting the binding of AP-1 or NF-B |
| CSN10851 | DMOG | 89464-63-1 | DMOG (Dimethyloxalylglycine) is a prolyl 4-hydroxylase inhibitor with IC50 value of 2uM. |
| CSN16738 | Ciclopirox | 29342-05-0 | Ciclopirox inhibits iron-dependent enzymes PHD2 pIC50 58 and deoxyhypusine hydroxylase It is an antifungal and iron-chelating agent |
| CSN17588 | BAY 87-2243 | 1227158-85-1 | BAY 87-2243 is a highly potent and selective inhibitor of hypoxia-induced HIF-1 activation |
| CSN19253 | 2-Methoxyestradiol | 362-07-2 | 2-methoxyestradiol is a natural metabolite of estrogen that is known to inhibit HIF-1 alpha with an IC50 of 0.71 ± 0.11 μM for the inhibition of BPAEC migration. |
| CSN23782 | Desidustat | 1616690-16-4 |
+1-708-781-1677
+1-708-286-6026
sales@csnpharm.com
